Galmed Pharma (GLMD) Misses Q4 EPS by 5c
Tweet
Share
E-mailGet Alerts GLMD Hot Sheet
Join SI Premium – FREE
Galmed Pharma (NASDAQ: GLMD) reported Q4 EPS of ($0.39), $0.05 worse than the analyst estimate of ($0.34).
For earnings history and earnings-related data on Galmed Pharma (GLMD) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Royal Caribbean to acquire 50% stake in Sandals Resorts for $3 billion
- UBS Upgrades Bajaj Finance Ltd. (BAF:IN) to Neutral
- MillerKnoll, Inc. (MLKN) Tops Q1 EPS by 18c ; Offers Guidance
Create E-mail Alert Related Categories
EarningsRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
